Loading…
The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro
Cell-surface heparan sulfate proteoglycans have been shown to participate in lipoprotein catabolism, but the roles of specific proteoglycan classes have not been examined previously. Here, we studied the involvement of the syndecan proteoglycan family. First, transfection of CHO cells with expressio...
Saved in:
Published in: | The Journal of clinical investigation 1997-09, Vol.100 (6), p.1611-1622 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c435t-da9027e5b8bda7b6ac1dfa847da8d9042f5976a0f12086cb0e6850b3b438d5373 |
---|---|
cites | |
container_end_page | 1622 |
container_issue | 6 |
container_start_page | 1611 |
container_title | The Journal of clinical investigation |
container_volume | 100 |
creator | Fuki, I V Kuhn, K M Lomazov, I R Rothman, V L Tuszynski, G P Iozzo, R V Swenson, T L Fisher, E A Williams, K J |
description | Cell-surface heparan sulfate proteoglycans have been shown to participate in lipoprotein catabolism, but the roles of specific proteoglycan classes have not been examined previously. Here, we studied the involvement of the syndecan proteoglycan family. First, transfection of CHO cells with expression vectors for several syndecan core proteins produced parallel increases in the cell association and degradation of lipoproteins enriched in lipoprotein lipase, a heparan-binding protein. Second, a chimeric construct, FcR-Synd1, that consists of the ectodomain of the IgG Fc receptor Ia linked to the highly conserved transmembrane and cytoplasmic domains of syndecan-1 directly mediated efficient internalization, in a process triggered by ligand clustering. Third, internalization of lipase-enriched lipoproteins via syndecan-1 and of clustered IgGs via the chimera showed identical kinetics (t1/2 = 1 h) and identical dose-response sensitivities to cytochalasin B, which disrupts microfilaments, and to genistein, which inhibits tyrosine kinases. In contrast, internalization of the receptor-associated protein, which proceeds via coated pits, showed a t1/2 < 15 min, limited sensitivity to cytochalasin B, and complete insensitivity to genistein. Thus, syndecan proteoglycans can directly mediate ligand catabolism through a pathway with characteristics distinct from coated pits, and might act as receptors for atherogenic lipoproteins and other ligands in vivo. |
doi_str_mv | 10.1172/jci119685 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_508343</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79279239</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-da9027e5b8bda7b6ac1dfa847da8d9042f5976a0f12086cb0e6850b3b438d5373</originalsourceid><addsrcrecordid>eNpVkU9PAyEQxTlotFYPfgATTiYeqrCw3eXgwTT-qWn0omfCsrMtDYUVaJP66UXbGE0mIQO_92bIQ-ickmtKq-JmqQ2lYlyXB2hASEFHomL1MTqJcUkI5bzkR-hIFIJTRgYovS0Ax61rQSuHO7Uydot9h_vgE_i53ebreI1f_AYsDqChTz5EvILWqGTcHBuXIDhlzWfuvfvWqrSA4OfgjMbW9P7Hy7iYWbwxKfhTdNgpG-Fsfw7R-8P92-RpNHt9nE7uZiPNWZlGrRKkqKBs6qZVVTNWmradqnnVqroVhBddKaqxIh0tSD3WDYH8a9KwhrO6LVnFhuh259uvm7yxBpeCsrIPZqXCVnpl5P8XZxZy7jeyJDXjLOsv9_rgP9YQk1yZqMFa5cCvo6xEkYuJDF7tQB18jAG63xmUyO9U5PNkukslsxd_l_ol95GwLwBYjlc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79279239</pqid></control><display><type>article</type><title>The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro</title><source>Open Access: PubMed Central</source><source>EZB Electronic Journals Library</source><creator>Fuki, I V ; Kuhn, K M ; Lomazov, I R ; Rothman, V L ; Tuszynski, G P ; Iozzo, R V ; Swenson, T L ; Fisher, E A ; Williams, K J</creator><creatorcontrib>Fuki, I V ; Kuhn, K M ; Lomazov, I R ; Rothman, V L ; Tuszynski, G P ; Iozzo, R V ; Swenson, T L ; Fisher, E A ; Williams, K J</creatorcontrib><description>Cell-surface heparan sulfate proteoglycans have been shown to participate in lipoprotein catabolism, but the roles of specific proteoglycan classes have not been examined previously. Here, we studied the involvement of the syndecan proteoglycan family. First, transfection of CHO cells with expression vectors for several syndecan core proteins produced parallel increases in the cell association and degradation of lipoproteins enriched in lipoprotein lipase, a heparan-binding protein. Second, a chimeric construct, FcR-Synd1, that consists of the ectodomain of the IgG Fc receptor Ia linked to the highly conserved transmembrane and cytoplasmic domains of syndecan-1 directly mediated efficient internalization, in a process triggered by ligand clustering. Third, internalization of lipase-enriched lipoproteins via syndecan-1 and of clustered IgGs via the chimera showed identical kinetics (t1/2 = 1 h) and identical dose-response sensitivities to cytochalasin B, which disrupts microfilaments, and to genistein, which inhibits tyrosine kinases. In contrast, internalization of the receptor-associated protein, which proceeds via coated pits, showed a t1/2 < 15 min, limited sensitivity to cytochalasin B, and complete insensitivity to genistein. Thus, syndecan proteoglycans can directly mediate ligand catabolism through a pathway with characteristics distinct from coated pits, and might act as receptors for atherogenic lipoproteins and other ligands in vivo.</description><identifier>ISSN: 0021-9738</identifier><identifier>DOI: 10.1172/jci119685</identifier><identifier>PMID: 9294130</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Chloroquine - pharmacology ; CHO Cells ; Cricetinae ; Cytochalasin B - pharmacology ; Dose-Response Relationship, Drug ; Genistein - pharmacology ; Heparin - pharmacology ; Humans ; Lipoprotein Lipase - metabolism ; Lipoproteins, LDL - metabolism ; Lipoproteins, LDL - pharmacokinetics ; Low Density Lipoprotein Receptor-Related Protein-1 ; Membrane Glycoproteins - genetics ; Membrane Glycoproteins - metabolism ; Proteoglycans - genetics ; Proteoglycans - metabolism ; Rats ; Receptors, IgG - genetics ; Receptors, IgG - metabolism ; Receptors, Immunologic - physiology ; Receptors, LDL - physiology ; Recombinant Fusion Proteins - pharmacology ; Syndecan-1 ; Syndecans ; Thrombospondins - pharmacology ; Transfection</subject><ispartof>The Journal of clinical investigation, 1997-09, Vol.100 (6), p.1611-1622</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-da9027e5b8bda7b6ac1dfa847da8d9042f5976a0f12086cb0e6850b3b438d5373</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC508343/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC508343/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9294130$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fuki, I V</creatorcontrib><creatorcontrib>Kuhn, K M</creatorcontrib><creatorcontrib>Lomazov, I R</creatorcontrib><creatorcontrib>Rothman, V L</creatorcontrib><creatorcontrib>Tuszynski, G P</creatorcontrib><creatorcontrib>Iozzo, R V</creatorcontrib><creatorcontrib>Swenson, T L</creatorcontrib><creatorcontrib>Fisher, E A</creatorcontrib><creatorcontrib>Williams, K J</creatorcontrib><title>The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>Cell-surface heparan sulfate proteoglycans have been shown to participate in lipoprotein catabolism, but the roles of specific proteoglycan classes have not been examined previously. Here, we studied the involvement of the syndecan proteoglycan family. First, transfection of CHO cells with expression vectors for several syndecan core proteins produced parallel increases in the cell association and degradation of lipoproteins enriched in lipoprotein lipase, a heparan-binding protein. Second, a chimeric construct, FcR-Synd1, that consists of the ectodomain of the IgG Fc receptor Ia linked to the highly conserved transmembrane and cytoplasmic domains of syndecan-1 directly mediated efficient internalization, in a process triggered by ligand clustering. Third, internalization of lipase-enriched lipoproteins via syndecan-1 and of clustered IgGs via the chimera showed identical kinetics (t1/2 = 1 h) and identical dose-response sensitivities to cytochalasin B, which disrupts microfilaments, and to genistein, which inhibits tyrosine kinases. In contrast, internalization of the receptor-associated protein, which proceeds via coated pits, showed a t1/2 < 15 min, limited sensitivity to cytochalasin B, and complete insensitivity to genistein. Thus, syndecan proteoglycans can directly mediate ligand catabolism through a pathway with characteristics distinct from coated pits, and might act as receptors for atherogenic lipoproteins and other ligands in vivo.</description><subject>Animals</subject><subject>Chloroquine - pharmacology</subject><subject>CHO Cells</subject><subject>Cricetinae</subject><subject>Cytochalasin B - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Genistein - pharmacology</subject><subject>Heparin - pharmacology</subject><subject>Humans</subject><subject>Lipoprotein Lipase - metabolism</subject><subject>Lipoproteins, LDL - metabolism</subject><subject>Lipoproteins, LDL - pharmacokinetics</subject><subject>Low Density Lipoprotein Receptor-Related Protein-1</subject><subject>Membrane Glycoproteins - genetics</subject><subject>Membrane Glycoproteins - metabolism</subject><subject>Proteoglycans - genetics</subject><subject>Proteoglycans - metabolism</subject><subject>Rats</subject><subject>Receptors, IgG - genetics</subject><subject>Receptors, IgG - metabolism</subject><subject>Receptors, Immunologic - physiology</subject><subject>Receptors, LDL - physiology</subject><subject>Recombinant Fusion Proteins - pharmacology</subject><subject>Syndecan-1</subject><subject>Syndecans</subject><subject>Thrombospondins - pharmacology</subject><subject>Transfection</subject><issn>0021-9738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNpVkU9PAyEQxTlotFYPfgATTiYeqrCw3eXgwTT-qWn0omfCsrMtDYUVaJP66UXbGE0mIQO_92bIQ-ickmtKq-JmqQ2lYlyXB2hASEFHomL1MTqJcUkI5bzkR-hIFIJTRgYovS0Ax61rQSuHO7Uydot9h_vgE_i53ebreI1f_AYsDqChTz5EvILWqGTcHBuXIDhlzWfuvfvWqrSA4OfgjMbW9P7Hy7iYWbwxKfhTdNgpG-Fsfw7R-8P92-RpNHt9nE7uZiPNWZlGrRKkqKBs6qZVVTNWmradqnnVqroVhBddKaqxIh0tSD3WDYH8a9KwhrO6LVnFhuh259uvm7yxBpeCsrIPZqXCVnpl5P8XZxZy7jeyJDXjLOsv9_rgP9YQk1yZqMFa5cCvo6xEkYuJDF7tQB18jAG63xmUyO9U5PNkukslsxd_l_ol95GwLwBYjlc</recordid><startdate>19970915</startdate><enddate>19970915</enddate><creator>Fuki, I V</creator><creator>Kuhn, K M</creator><creator>Lomazov, I R</creator><creator>Rothman, V L</creator><creator>Tuszynski, G P</creator><creator>Iozzo, R V</creator><creator>Swenson, T L</creator><creator>Fisher, E A</creator><creator>Williams, K J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19970915</creationdate><title>The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro</title><author>Fuki, I V ; Kuhn, K M ; Lomazov, I R ; Rothman, V L ; Tuszynski, G P ; Iozzo, R V ; Swenson, T L ; Fisher, E A ; Williams, K J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-da9027e5b8bda7b6ac1dfa847da8d9042f5976a0f12086cb0e6850b3b438d5373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Animals</topic><topic>Chloroquine - pharmacology</topic><topic>CHO Cells</topic><topic>Cricetinae</topic><topic>Cytochalasin B - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Genistein - pharmacology</topic><topic>Heparin - pharmacology</topic><topic>Humans</topic><topic>Lipoprotein Lipase - metabolism</topic><topic>Lipoproteins, LDL - metabolism</topic><topic>Lipoproteins, LDL - pharmacokinetics</topic><topic>Low Density Lipoprotein Receptor-Related Protein-1</topic><topic>Membrane Glycoproteins - genetics</topic><topic>Membrane Glycoproteins - metabolism</topic><topic>Proteoglycans - genetics</topic><topic>Proteoglycans - metabolism</topic><topic>Rats</topic><topic>Receptors, IgG - genetics</topic><topic>Receptors, IgG - metabolism</topic><topic>Receptors, Immunologic - physiology</topic><topic>Receptors, LDL - physiology</topic><topic>Recombinant Fusion Proteins - pharmacology</topic><topic>Syndecan-1</topic><topic>Syndecans</topic><topic>Thrombospondins - pharmacology</topic><topic>Transfection</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fuki, I V</creatorcontrib><creatorcontrib>Kuhn, K M</creatorcontrib><creatorcontrib>Lomazov, I R</creatorcontrib><creatorcontrib>Rothman, V L</creatorcontrib><creatorcontrib>Tuszynski, G P</creatorcontrib><creatorcontrib>Iozzo, R V</creatorcontrib><creatorcontrib>Swenson, T L</creatorcontrib><creatorcontrib>Fisher, E A</creatorcontrib><creatorcontrib>Williams, K J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fuki, I V</au><au>Kuhn, K M</au><au>Lomazov, I R</au><au>Rothman, V L</au><au>Tuszynski, G P</au><au>Iozzo, R V</au><au>Swenson, T L</au><au>Fisher, E A</au><au>Williams, K J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>1997-09-15</date><risdate>1997</risdate><volume>100</volume><issue>6</issue><spage>1611</spage><epage>1622</epage><pages>1611-1622</pages><issn>0021-9738</issn><abstract>Cell-surface heparan sulfate proteoglycans have been shown to participate in lipoprotein catabolism, but the roles of specific proteoglycan classes have not been examined previously. Here, we studied the involvement of the syndecan proteoglycan family. First, transfection of CHO cells with expression vectors for several syndecan core proteins produced parallel increases in the cell association and degradation of lipoproteins enriched in lipoprotein lipase, a heparan-binding protein. Second, a chimeric construct, FcR-Synd1, that consists of the ectodomain of the IgG Fc receptor Ia linked to the highly conserved transmembrane and cytoplasmic domains of syndecan-1 directly mediated efficient internalization, in a process triggered by ligand clustering. Third, internalization of lipase-enriched lipoproteins via syndecan-1 and of clustered IgGs via the chimera showed identical kinetics (t1/2 = 1 h) and identical dose-response sensitivities to cytochalasin B, which disrupts microfilaments, and to genistein, which inhibits tyrosine kinases. In contrast, internalization of the receptor-associated protein, which proceeds via coated pits, showed a t1/2 < 15 min, limited sensitivity to cytochalasin B, and complete insensitivity to genistein. Thus, syndecan proteoglycans can directly mediate ligand catabolism through a pathway with characteristics distinct from coated pits, and might act as receptors for atherogenic lipoproteins and other ligands in vivo.</abstract><cop>United States</cop><pmid>9294130</pmid><doi>10.1172/jci119685</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9738 |
ispartof | The Journal of clinical investigation, 1997-09, Vol.100 (6), p.1611-1622 |
issn | 0021-9738 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_508343 |
source | Open Access: PubMed Central; EZB Electronic Journals Library |
subjects | Animals Chloroquine - pharmacology CHO Cells Cricetinae Cytochalasin B - pharmacology Dose-Response Relationship, Drug Genistein - pharmacology Heparin - pharmacology Humans Lipoprotein Lipase - metabolism Lipoproteins, LDL - metabolism Lipoproteins, LDL - pharmacokinetics Low Density Lipoprotein Receptor-Related Protein-1 Membrane Glycoproteins - genetics Membrane Glycoproteins - metabolism Proteoglycans - genetics Proteoglycans - metabolism Rats Receptors, IgG - genetics Receptors, IgG - metabolism Receptors, Immunologic - physiology Receptors, LDL - physiology Recombinant Fusion Proteins - pharmacology Syndecan-1 Syndecans Thrombospondins - pharmacology Transfection |
title | The syndecan family of proteoglycans. Novel receptors mediating internalization of atherogenic lipoproteins in vitro |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A12%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20syndecan%20family%20of%20proteoglycans.%20Novel%20receptors%20mediating%20internalization%20of%20atherogenic%20lipoproteins%20in%20vitro&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Fuki,%20I%20V&rft.date=1997-09-15&rft.volume=100&rft.issue=6&rft.spage=1611&rft.epage=1622&rft.pages=1611-1622&rft.issn=0021-9738&rft_id=info:doi/10.1172/jci119685&rft_dat=%3Cproquest_pubme%3E79279239%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c435t-da9027e5b8bda7b6ac1dfa847da8d9042f5976a0f12086cb0e6850b3b438d5373%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=79279239&rft_id=info:pmid/9294130&rfr_iscdi=true |